D. E. Shaw & Co., Inc. Amylyx Pharmaceuticals, Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 691,066 shares of AMLX stock, worth $3.66 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

691,066

Holding current value

$3.66 Million

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.65 - $3.24 $1.02 Million - $2 Million	-617,115 Reduced 47.17%	691,066 $2.24 Million
Q2 2024 Aug 14, 2024	BUY	$1.62 - $2.71 $430,268 - $719,770	265,598 Added 25.47%	1,308,181 $2.49 Million
Q1 2024 May 15, 2024	BUY	$2.71 - $19.57 $1.34 Million - $9.7 Million	495,618 Added 90.61%	1,042,583 $2.96 Million
Q4 2023 Feb 14, 2024	SELL	$12.07 - $18.46 $2.57 Million - $3.94 Million	-213,325 Reduced 28.06%	546,965 $8.05 Million
Q3 2023 Nov 14, 2023	SELL	$18.08 - $23.45 $15 Million - $19.5 Million	-829,754 Reduced 52.18%	760,290 $13.9 Million
Q2 2023 Aug 14, 2023	SELL	$20.98 - $31.42 $9.07 Million - $13.6 Million	-432,326 Reduced 21.38%	1,590,044 $34.3 Million
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $17.7 Million - $26.1 Million	638,638 Added 46.15%	2,022,370 $59.3 Million
Q4 2022 Feb 14, 2023	BUY	$29.75 - $39.26 $36.3 Million - $48 Million	1,221,467 Added 752.76%	1,383,732 $51.1 Million
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $2.78 Million - $5.02 Million	162,265 New	162,265 $4.57 Million

Others Institutions Holding AMLX

# of Institutions

127

Shares Held

44.4M

Call Options Held

235K

Put Options Held

530K

View Full List

About Amylyx Pharmaceuticals, Inc.

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $310M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

More about AMLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account